Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endemic mycoses: a treatment update.

O Lortholary1, D W Denning, B Dupont

  • 1Service de Médecine Interne, Centre de Recherche en Pathologie Infectieuse et Tropicale, Hôpital Avicenne, Université Paris Nord, Bobigny, France. olortho@pasteur.fr

The Journal of Antimicrobial Chemotherapy
|May 1, 1999
PubMed
Summary

This study reviews antifungal treatments for endemic mycoses. Amphotericin B is key for severe infections, while azoles like itraconazole and fluconazole offer alternatives for specific fungal diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas(lpr) mice from early lethality.

Journal of immunology (Baltimore, Md. : 1950)·1997
Same author

Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir.

AIDS (London, England)·1997
Same author

Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates.

AIDS (London, England)·1997
Same author

Antifungal prophylaxis during neutropenia and immunodeficiency.

Clinical microbiology reviews·1997
Same author

Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.

Archives of dermatology·1997
Same author

Search for infectious HIV in gingival crevicular fluid and saliva of advanced AIDS patients with severe periodontitis.

AIDS (London, England)·1997

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Endemic mycoses pose significant global health challenges.
  • Increasing frequency is linked to the spread of Human Immunodeficiency Virus (HIV) infection.
  • These fungal infections affect both immunocompetent and immunocompromised individuals.

Purpose of the Study:

  • To review current antifungal treatment strategies for endemic mycoses.
  • To highlight the efficacy of various antifungal agents.
  • To discuss the role of these agents in different patient populations and infection types.

Main Methods:

  • Literature review of established and emerging antifungal therapies.
  • Analysis of drug efficacy based on clinical data and patient outcomes.

Related Experiment Videos

  • Comparison of treatment options for specific endemic fungal infections.

    • Main Results:

    • Amphotericin B is the primary treatment for life-threatening endemic mycoses.
    • Itraconazole is effective for non-life-threatening histoplasmosis, blastomycosis, and as prophylaxis in AIDS patients.
    • Fluconazole and itraconazole are options for coccidioidomycosis, though fluconazole has limited efficacy against other endemic mycoses.

    Conclusions:

    • Antifungal drug selection depends on the specific mycosis, host immune status, and infection severity.
    • Itraconazole and fluconazole offer valuable therapeutic options for various endemic mycoses.
    • Ongoing research into new antifungal agents is crucial for addressing treatment challenges.